Blood Pressure and Kidney Damage: A Patient's Guide to How Hypertension Hurts Your Kidneys and How to Protect Them

A patient sits across from me and I’m explaining why their blood pressure needs to be tighter. They say what I hear all the time: “But my kidneys feel fine.” That’s the heart of the problem. The kidneys rarely complain until they’re in real trouble. Hypertension damages them quietly, over years, with no pain and no obvious symptoms, and by the time a patient notices ankle swelling, fatigue, or a new diagnosis of chronic kidney disease, a substantial fraction of the nephrons (the tiny filtering units inside each kidney) are already gone and they don’t come back.

This matters because hypertension is the second leading cause of end-stage kidney disease in the United States, behind only diabetes. About 1 in 10 American adults with hypertension already has stage 3 or worse chronic kidney disease, and most don’t know it. Globally, high systolic blood pressure is one of the top three modifiable risk factors driving kidney disease, alongside body weight and glucose. The good news is that we know how to prevent and slow this damage, and the tools have never been better. Between modern blood pressure targets, the RAAS blockers we’ve had for decades, and the newer SGLT2 inhibitors and finerenone that have transformed nephrology practice over the last 5 years, we can meaningfully protect a hypertensive patient’s kidneys.

This guide walks through what happens inside the kidney when blood pressure is chronically high, what tests catch the damage early, what blood pressure targets the trials support, which medications change the trajectory, what to do at home, and what to expect at each stage of monitoring and treatment.

How Does High Blood Pressure Damage the Kidneys?

Each kidney contains about a million nephrons (the microscopic filtering units that clean the blood). When systemic blood pressure is chronically high, the small arteries feeding the nephrons either constrict (starving the nephron) or fail to constrict (transmitting the high pressure into the filter and damaging it). Over years, the filters develop scarring (called hypertensive nephrosclerosis), leak protein, and lose function. The damage is silent until a substantial fraction of nephrons are gone.

How the Filter Normally Works

Each nephron has two parts. The glomerulus is a tuft of tiny blood vessels that acts like a high-pressure sieve, filtering fluid out of the blood. The tubule is a long tube that fine-tunes the filtered fluid, reabsorbing what the body needs and secreting what it doesn’t, before what’s left becomes urine.

Blood enters the glomerulus through a small artery called the afferent arteriole, gets filtered across a specialized membrane, and exits through another small artery called the efferent arteriole. Pressure inside the glomerulus has to be tight enough to drive filtration but not so high that the sieve breaks down.

What Goes Wrong with Chronic Hypertension

When systemic blood pressure is chronically elevated, the kidney tries to protect itself. The afferent arteriole constricts to reduce the pressure transmitted to the glomerulus. Over years of sustained high pressure, the wall of the afferent arteriole thickens and becomes infiltrated with a glassy material in a process called hyalinosis. Some arterioles scar down and close entirely, leaving the nephrons they feed to die from lack of blood supply. Other arterioles fail to constrict enough and transmit the high pressure straight into the glomerulus, which then develops what’s called glomerular hypertension and hyperfiltration. Some nephrons starve while others are overworked, and the overall kidney loses filtering capacity in a patchy pattern that pathologists call hypertensive nephrosclerosis.

The hyperfiltering glomeruli pay a price. The high pressure stresses the podocytes, specialized cells that wrap around the glomerular capillaries and form the final barrier keeping protein in the blood. Stressed podocytes detach or die. Once they’re gone, the filtration barrier leaks protein into the urine. This proteinuria is more than a marker of damage. It actively drives more damage. Filtered protein gets reabsorbed by downstream tubules, which activates inflammatory pathways that scar the tissue between tubules.

The RAAS Loop That Makes It Worse

Underneath this, the renin-angiotensin-aldosterone system (RAAS) is activated inappropriately in the hypertensive kidney. Angiotensin II constricts the efferent arteriole more than the afferent, which further raises glomerular pressure. It also promotes oxidative stress, inflammation, and direct scarring. This is why RAAS blockers (lisinopril, losartan, and the related drugs) are so effective at protecting the kidney: they interrupt this maladaptive amplification loop.

Why You Probably Don’t Feel It

The kidney has enormous reserve. A patient can lose half of their nephrons and still have a normal serum creatinine, a normal eGFR, and feel completely fine. By the time creatinine rises above the upper limit of normal on a routine lab, the damage is often substantial and frequently not fully reversible. Symptoms (fatigue, leg swelling, getting up at night to urinate, loss of appetite) usually appear only when kidney function has dropped below about 30 percent of normal.

What Tests Catch Kidney Damage Early?

Two simple tests catch hypertensive kidney damage years before symptoms appear: a serum creatinine with estimated glomerular filtration rate (eGFR), and a urine albumin-to-creatinine ratio (UACR) on a spot urine sample. UACR is more sensitive and often abnormal years before eGFR starts to fall. Both should be checked at least annually in every patient with hypertension.

Serum Creatinine and eGFR

Serum creatinine is a waste product of muscle metabolism that the kidneys filter out. When kidney function drops, creatinine builds up. From the creatinine level, age, and sex, lab algorithms calculate eGFR, the estimated glomerular filtration rate, in mL/min/1.73m squared.

Stages of chronic kidney disease by eGFR:

Stage 1: eGFR 90 or higher with evidence of kidney damage (proteinuria or abnormal imaging).

Stage 2: eGFR 60 to 89 with evidence of damage.

Stage 3a: eGFR 45 to 59.

Stage 3b: eGFR 30 to 44.

Stage 4: eGFR 15 to 29.

Stage 5: eGFR under 15 (kidney failure, often requiring dialysis or transplant).

eGFR has limitations. It’s an estimate, not a direct measure. It depends on accurate muscle mass assumptions, which can be off in very muscular or very thin patients. A small drop on a single test isn’t necessarily meaningful; the trend over multiple tests matters more than any single value.

Urine Albumin-to-Creatinine Ratio (UACR)

UACR measures how much of a specific blood protein called albumin is leaking through the kidney filter into the urine. It’s reported in mg/g (milligrams of albumin per gram of urine creatinine).

Normal: UACR under 30 mg/g.

Moderately increased (microalbuminuria): 30 to 300 mg/g.

Severely increased (macroalbuminuria): over 300 mg/g.

UACR is the most sensitive early marker of kidney damage in hypertension. It’s often abnormal years before eGFR starts to fall. Patients are often surprised when I order it because their urine looks fine, but the protein leak is invisible to the naked eye.

When to Check These Tests

Every hypertensive patient should have eGFR and UACR checked at least annually. Patients with established kidney disease, diabetes, or proteinuria should be checked more often, sometimes every 3 to 6 months. New BP medication changes or significant clinical changes warrant repeat testing.

Other Tests Sometimes Used

A 24-hour urine collection can quantify proteinuria more precisely but is less convenient than UACR.

Kidney ultrasound can show structural abnormalities, kidney size, and rule out obstruction.

Renal artery imaging (Doppler ultrasound, MR angiography, or CT angiography) is used when renal artery stenosis (narrowing of an artery to the kidney) is suspected.

Kidney biopsy is reserved for cases where the diagnosis is uncertain and would change management.

What Blood Pressure Should I Aim For?

For most patients with kidney disease and hypertension, the target is under 130/80. The SPRINT trial showed that an even tighter target of under 120 systolic reduces cardiovascular and kidney events in patients who can tolerate the medications. For patients with diabetes and kidney disease, under 130/80 is also the standard. For older patients or those who get lightheaded on standing, the target is individualized.

Where the Targets Come From

The SPRINT trial randomized non-diabetic patients with cardiovascular risk to a systolic target of under 120 vs under 140. The intensive group had fewer cardiovascular events, fewer deaths, and (in patients without diabetes) slower kidney function decline. Subsequent analyses showed the benefits extended to patients with chronic kidney disease.

Other trials in patients with diabetes showed less dramatic benefit from very tight control, partly because of competing risks (hypoglycemia, falls) in this group. The current target for most diabetic patients with kidney disease is under 130/80.

Why Lower Is Generally Better for the Kidney

Lower systemic blood pressure means lower glomerular pressure, less mechanical stress on the filter, less proteinuria, and slower nephron loss. Every 10 mmHg drop in systolic blood pressure is associated with measurably slower kidney function decline in most studies.

When Lower Isn’t Better

Aggressive blood pressure lowering can cause symptomatic hypotension, falls, fainting, and acute kidney injury (a sudden drop in kidney function from inadequate perfusion). Older patients, patients on multiple medications, and patients with limited mobility need individualized targets.

For these patients, a target of under 140/90 may be appropriate, especially if a tighter target requires more medications than can be safely tolerated. The team weighs the long-term kidney benefit against the immediate fall and hypotension risk.

Home Blood Pressure Monitoring

Office blood pressure measurements have substantial limitations: white-coat effect (higher in clinic than at home), masked hypertension (lower in clinic than at home), and just plain variability. Home monitoring with a validated upper-arm cuff (not a wrist cuff) gives a more reliable picture.

Standard home protocol: take blood pressure twice in the morning and twice in the evening, with 1 to 2 minutes between readings, after sitting quietly for 5 minutes, with the arm supported at heart level. Log the readings. Bring the log to clinic visits.

What Medications Protect the Kidney?

The cornerstone is RAAS blockade with an ACE inhibitor (lisinopril, ramipril, enalapril) or ARB (losartan, valsartan, candesartan, telmisartan). These drugs lower blood pressure, reduce proteinuria, and slow kidney decline beyond what the blood pressure drop alone would predict. SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) have transformed kidney protection in the past 5 years and are now standard in many patients regardless of diabetes status. Finerenone adds further benefit in diabetic kidney disease. Combination therapy is often needed.

ACE Inhibitors and ARBs

ACE inhibitors and ARBs block the renin-angiotensin-aldosterone system. They lower blood pressure, reduce glomerular pressure, decrease proteinuria, and slow the progression of kidney disease.

ACE inhibitors include lisinopril, ramipril, enalapril, benazepril. The most common side effect is dry cough (about 10 to 15 percent of patients), which usually requires switching to an ARB.

ARBs include losartan, valsartan, candesartan, telmisartan, irbesartan. ARBs don’t cause cough and are generally well-tolerated.

Don’t combine an ACE inhibitor with an ARB. The combination doesn’t add benefit and raises the risk of hyperkalemia (high potassium) and acute kidney injury.

For more on this drug class, see our guide to ARBs.

SGLT2 Inhibitors

SGLT2 inhibitors are a newer class originally developed for diabetes that turned out to have dramatic kidney protection benefits. The CREDENCE and DAPA-CKD trials showed substantial reductions in kidney failure and cardiovascular events. EMPA-KIDNEY extended the benefits to patients without diabetes.

Drugs in the class: empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana), ertugliflozin (Steglatro).

How they work for the kidney: they reduce glomerular hyperfiltration, lower intraglomerular pressure, reduce proteinuria, and have anti-inflammatory effects in the kidney.

Side effects: genital fungal infections (more common in patients prone to them), rare risk of ketoacidosis especially in patients with type 1 diabetes, modest blood pressure lowering, modest weight loss (often welcome), and rare risk of urinary tract infections.

Most cardiologists and nephrologists now consider SGLT2 inhibitors standard for patients with kidney disease and either diabetes, heart failure, or significant proteinuria, regardless of diabetes status.

Finerenone

Finerenone (Kerendia) is a non-steroidal mineralocorticoid receptor antagonist that further reduces inflammation and fibrosis in the kidney. The FIDELIO-DKD and FIGARO-DKD trials showed substantial reductions in kidney and cardiovascular events in patients with diabetic kidney disease.

It’s typically added on top of an ACE inhibitor or ARB and an SGLT2 inhibitor, in patients with persistent proteinuria despite the other agents.

Main side effect: hyperkalemia (high potassium), which requires monitoring.

Diuretics

Diuretics help lower blood pressure and manage fluid retention. They’re often part of combination therapy in resistant hypertension.

Thiazide diuretics (hydrochlorothiazide, chlorthalidone) are first-line for blood pressure. Chlorthalidone has more evidence for cardiovascular benefit than hydrochlorothiazide.

Loop diuretics (furosemide, torsemide, bumetanide) are used in patients with advanced kidney disease (where thiazides become less effective) or significant fluid overload.

Calcium Channel Blockers

Calcium channel blockers (amlodipine, diltiazem, verapamil) lower blood pressure and are often part of combination therapy. Amlodipine in particular is well-tolerated and effective in combination with an ACE inhibitor or ARB.

Beta-Blockers

Beta-blockers (metoprolol, atenolol, carvedilol, nebivolol) are useful in specific scenarios (after heart attack, in heart failure with reduced ejection fraction, with certain arrhythmias) but aren’t first-line for hypertension or kidney protection alone.

Aldosterone Antagonists (Spironolactone, Eplerenone)

Spironolactone is often added in resistant hypertension (when 3 or more medications including a diuretic don’t get to goal). The PATHWAY-2 trial showed spironolactone was the best single fourth agent in this scenario.

Hyperkalemia is the main concern, especially when combined with ACE inhibitors or ARBs.

Combination Therapy

Most patients with kidney disease and hypertension need 2 to 4 medications to reach blood pressure targets. Common effective combinations:

ACE inhibitor or ARB plus thiazide.

ACE inhibitor or ARB plus calcium channel blocker.

ACE inhibitor or ARB plus calcium channel blocker plus thiazide.

Add SGLT2 inhibitor for kidney and cardiovascular benefit.

Add finerenone for diabetic kidney disease with proteinuria.

Add spironolactone for resistant cases.

What Lifestyle Changes Make a Difference?

Reducing sodium to under 2 grams a day, losing weight if overweight, regular aerobic exercise, limiting alcohol, and quitting smoking all have meaningful effects on blood pressure and kidney protection. The DASH diet has the best evidence for blood pressure lowering through dietary changes. These changes work in combination with medications, not as a substitute.

Sodium Reduction

The American Heart Association recommends under 2.3 grams of sodium per day, with an ideal target of under 1.5 grams for most adults. Most Americans consume 3 to 5 grams per day. The biggest sources are processed and restaurant food, not the salt shaker.

Practical strategies: read food labels, choose fresh over processed, cook at home, limit restaurant meals, use spices and herbs instead of salt for flavor.

Each 1-gram reduction in sodium produces a modest blood pressure drop on average (a few mmHg systolic), but the effect is larger in salt-sensitive patients (often African American patients and older patients).

DASH Diet

The Dietary Approaches to Stop Hypertension (DASH) diet emphasizes fruits, vegetables, whole grains, lean protein, low-fat dairy, nuts, and seeds while limiting red meat, sweets, and sodium. The DASH-Sodium trial showed combined DASH plus sodium restriction produced blood pressure reductions of 8 to 14 mmHg systolic, comparable to a single antihypertensive medication.

Weight Loss

Each kilogram of weight loss is associated with about 1 mmHg drop in blood pressure. A 5 to 10 percent body weight loss can produce meaningful blood pressure reductions and may also reduce proteinuria.

For overweight patients, sustained weight loss is hard. Structured programs, GLP-1 medications, or bariatric surgery may be appropriate for selected patients.

Exercise

Regular aerobic exercise (30 to 60 minutes most days of the week) lowers systolic blood pressure by an average of 5 to 7 mmHg. Resistance training adds modest additional benefit. The blood pressure benefit starts within weeks of starting a regular routine.

Alcohol

Heavy drinking raises blood pressure. The 2025 dietary guidelines lean toward minimizing alcohol for cardiovascular health. For hypertensive patients, limiting to one drink per day for women and one to two for men is reasonable, with less being better.

Smoking

Smoking damages the kidney directly and dramatically raises cardiovascular risk. See our full guide to smoking cessation.

Sleep and Stress

Inadequate sleep (less than 6 hours per night) and unmanaged chronic stress raise blood pressure. Sleep apnea, in particular, is a common cause of resistant hypertension and warrants screening in patients who snore, are obese, or have daytime sleepiness.

How Should I Prepare for a Kidney-Focused Visit?

Bring your home blood pressure log for the past 2 to 4 weeks. Bring a complete medication list with doses. Bring any recent lab work (eGFR, UACR, electrolytes). Be prepared to discuss symptoms (fatigue, swelling, urinary changes). Bring family history of kidney disease, diabetes, or hypertension. Plan to spend 30 to 60 minutes at the visit.

Home Blood Pressure Log

The single most useful thing you can bring. Take 4 readings per day (2 morning, 2 evening), log them, average over the week. The home average is a much better guide to treatment than any single office reading.

Medication List

Names, doses, when taken, and any side effects. Include over-the-counter medications (especially NSAIDs like ibuprofen and naproxen, which can damage the kidney), supplements, and herbal preparations.

Lab Work

Recent eGFR, UACR, basic metabolic panel, fasting glucose or A1c if diabetic. If labs are due, request them before the visit so results are available.

Symptoms to Mention

Fatigue. Leg swelling. Getting up to urinate at night (nocturia). Changes in urine appearance (foamy urine can suggest proteinuria). Lightheadedness on standing. Headaches. Vision changes. Chest pain or shortness of breath.

Family History

Anyone in the family with kidney disease, kidney failure, dialysis, kidney transplant, polycystic kidney disease. Anyone with diabetes or early-onset hypertension.

Questions to Ask

What’s my current eGFR and UACR? How have they changed over time? What’s my blood pressure target? Are my medications optimized? Should I be on an SGLT2 inhibitor? Are there lifestyle changes that would help?

What Should I Watch for at Home?

Monitor blood pressure twice a day. Watch for new symptoms: increasing fatigue, leg swelling, foamy urine, getting up multiple times at night to urinate, lightheadedness. Take medications consistently and at the prescribed times. Call the team for sustained blood pressure above target, new symptoms, or any side effects from medications.

Daily Blood Pressure Monitoring

Use a validated upper-arm cuff. Take morning readings before medications. Take evening readings before dinner. Average over the week. Bring the log to every visit.

If you see sustained readings above your target (more than 3 days), call the office for a medication adjustment.

New Symptoms That Warrant a Call

Increasing leg swelling. New shortness of breath. Foamy urine that wasn’t there before. Getting up 3 or more times a night to urinate when this wasn’t typical for you. Lightheadedness or fainting on standing. New muscle cramps or weakness (possible electrolyte issue).

Symptoms That Warrant the ER

Severe shortness of breath. Chest pain. Confusion. Inability to urinate. Severe headache with vision changes. Severe lightheadedness or fainting.

Medication Adherence

Take medications at the same time each day. Use a pillbox or smartphone reminder. Don’t stop medications without talking to your team, even if you feel fine. Most blood pressure medications are taken indefinitely.

Watch for NSAIDs

Over-the-counter NSAIDs (ibuprofen, naproxen, ketorolac) can damage the kidney, especially when combined with ACE inhibitors or ARBs and diuretics (the “triple whammy”). Acetaminophen is safer for routine pain relief in patients with kidney disease.

Hydration

Stay well-hydrated unless your team has told you to restrict fluids (which is uncommon in early kidney disease). Aim for 1.5 to 2 liters of water per day. More in hot weather or during exercise.

How Often Should I Be Seen and Tested?

Patients with hypertension and no kidney disease: annual eGFR and UACR, with blood pressure reviewed at every visit (typically every 6 to 12 months). Patients with chronic kidney disease stage 1 to 3: every 3 to 6 months with eGFR and UACR. Stage 4: monthly to every 3 months. Stage 5: very close monitoring with nephrology team.

Routine Visits

Every 6 to 12 months for stable patients with controlled blood pressure and no kidney disease.

Every 3 to 6 months for patients with kidney disease stage 1 to 3 or after a medication change.

Monthly to every 3 months for patients with advanced kidney disease.

Lab Work

eGFR and UACR annually for hypertensive patients without kidney disease.

eGFR, UACR, and electrolytes (especially potassium) every 3 to 6 months for kidney disease patients.

More frequent labs after medication changes, especially adding RAAS blockers, SGLT2 inhibitors, or finerenone (check eGFR and potassium 1 to 2 weeks after starting).

When to See a Nephrologist

eGFR persistently under 30. Rapidly declining eGFR (more than 5 mL/min per year). Severe proteinuria (UACR over 300 to 500). Resistant hypertension. Suspected secondary cause of kidney disease. Preparation for renal replacement therapy.

Common Questions Patients Ask Me

Can kidney damage from hypertension be reversed?

Some early damage (microalbuminuria, mild eGFR drop) can stabilize or even improve with aggressive blood pressure control and RAAS blockade. Established scarring (visible on biopsy) typically can’t be reversed, but progression can be slowed substantially. Earlier intervention means better outcomes.

Why is my eGFR slightly lower this year than last?

A small change in eGFR can be normal variation, especially with hydration status, recent illness, or new medications. A persistent downward trend over multiple tests is more concerning. Your team will look at the trend, not any single value.

Do I need to see a nephrologist?

Most patients with mild kidney disease (stage 1 to 2) can be managed by their primary care doctor or cardiologist. Stage 3 patients often benefit from nephrology consultation, especially if proteinuria is significant or progression is rapid. Stage 4 and beyond should have a nephrologist involved.

Are NSAIDs really that dangerous?

Yes, especially in combination with RAAS blockers and diuretics. Even short courses can produce acute kidney injury in susceptible patients. Use acetaminophen for routine pain when possible.

Will I need dialysis?

Most patients with hypertensive kidney damage who are appropriately treated never need dialysis. The risk depends on the starting eGFR, the rate of decline, the degree of proteinuria, and whether risk factors are controlled. Aggressive management substantially reduces the risk of progression to end-stage disease.

Can I exercise?

Yes. Regular aerobic exercise is recommended. Avoid extreme exertion in heat without adequate hydration. Discuss specific guidance with your team if you have advanced kidney disease.

Should I limit protein?

Modest protein restriction (about 0.8 g/kg/day) has been studied in kidney disease and shows variable benefit. Severe restriction is not recommended because of malnutrition risk. Most patients should eat balanced meals and discuss specific dietary targets with their team or a registered dietitian.

What about contrast dye for CT scans?

IV contrast can cause acute kidney injury in patients with low eGFR. The risk is meaningfully lower with modern lower-osmolar contrast agents than with older formulations. If you have an eGFR under 30 and a contrast study is recommended, discuss alternatives or hydration strategies with your team.

Will my children get this?

There’s some genetic component to both hypertension and kidney disease. Your children should be screened for high blood pressure starting in young adulthood, especially if they have other risk factors (obesity, sedentary lifestyle, family history).

Can supplements help?

No supplement has solid evidence for preventing or slowing hypertensive kidney damage. Some supplements (potassium, magnesium, beet juice) modestly lower blood pressure in some studies, but the effects are small compared to medications. Discuss any supplements with your team before starting.

What about resistant hypertension?

Resistant hypertension is blood pressure above target despite 3 or more medications including a diuretic. Workup includes confirming adherence, checking for white-coat effect with home or ambulatory monitoring, looking for secondary causes (renal artery stenosis, sleep apnea, primary aldosteronism), and adding spironolactone or other agents.

Can I take ACE inhibitors if I’m pregnant?

No. ACE inhibitors and ARBs are contraindicated in pregnancy. Talk to your team about switching to pregnancy-safe alternatives if you’re planning a pregnancy.

Reference Tables

Stages of Chronic Kidney Disease

UACR Categories

Key Kidney-Protective Medications

A Final Note From Me

Hypertensive kidney damage is preventable and slowable. Most kidney loss happens silently over years, and most patients don’t know it’s happening until a substantial fraction of nephrons are gone. The two simple tests that catch it (eGFR and UACR) should be done annually in every patient with hypertension. The treatments that work (aggressive BP control, RAAS blockade, SGLT2 inhibitors, finerenone in diabetic kidney disease, lifestyle changes) work best when started early.

If you have hypertension, please get tested. Get your blood pressure to target. If you have proteinuria or reduced kidney function, please take the medications consistently and follow up regularly. The trajectory of kidney function depends on what we do over years and decades, not over weeks.

If you have questions about your specific kidney numbers, want help interpreting recent labs, or need to think through medication options, our office can help. To get in touch, visit our practice website. For coordinated care, we work with the nephrology and prevention team at San Diego Cardiovascular Associates.

References

1. Whelton PK, Carey RM, Aronow WS, et al. “2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.” Journal of the American College of Cardiology. 2018;71:e127-e248.

2. SPRINT Research Group. “A Randomized Trial of Intensive versus Standard Blood-Pressure Control.” New England Journal of Medicine. 2015;373:2103-2116.

3. Perkovic V, Jardine MJ, Neal B, et al. “Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE).” New England Journal of Medicine. 2019;380:2295-2306.

4. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. “Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD).” New England Journal of Medicine. 2020;383:1436-1446.

5. EMPA-KIDNEY Collaborative Group. “Empagliflozin in Patients with Chronic Kidney Disease.” New England Journal of Medicine. 2023;388:117-127.

6. Bakris GL, Agarwal R, Anker SD, et al. “Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes (FIDELIO-DKD).” New England Journal of Medicine. 2020;383:2219-2229.

7. Williams B, MacDonald TM, Morant S, et al. “Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2).” Lancet. 2015;386:2059-2068.

8. “KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.” Kidney International. 2024.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.